- Home
- LPTX vs CLRB Comparison
LPTX vs CLRB Comparison
Compare LPTX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CLRB
- Stock Information
- Founded
- LPTX 2011
- CLRB 2002
- Country
- LPTX United States
- CLRB United States
- Employees
- LPTX N/A
- CLRB N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- CLRB Health Care
- Exchange
- LPTX Nasdaq
- CLRB Nasdaq
- Market Cap
- LPTX 14.7M
- CLRB 14.2M
- IPO Year
- LPTX N/A
- CLRB N/A
- Fundamental
- Price
- LPTX $0.31
- CLRB $4.44
- Analyst Decision
- LPTX Hold
- CLRB Hold
- Analyst Count
- LPTX 1
- CLRB 2
- Target Price
- LPTX N/A
- CLRB N/A
- AVG Volume (30 Days)
- LPTX 661.1K
- CLRB 113.2K
- Earning Date
- LPTX 08-19-2025
- CLRB 08-14-2025
- Dividend Yield
- LPTX N/A
- CLRB N/A
- EPS Growth
- LPTX N/A
- CLRB N/A
- EPS
- LPTX N/A
- CLRB N/A
- Revenue
- LPTX N/A
- CLRB N/A
- Revenue This Year
- LPTX N/A
- CLRB N/A
- Revenue Next Year
- LPTX N/A
- CLRB N/A
- P/E Ratio
- LPTX N/A
- CLRB N/A
- Revenue Growth
- LPTX N/A
- CLRB N/A
- 52 Week Low
- LPTX $0.22
- CLRB $4.36
- 52 Week High
- LPTX $4.79
- CLRB $68.70
- Technical
- Relative Strength Index (RSI)
- LPTX 43.86
- CLRB 35.40
- Support Level
- LPTX $0.30
- CLRB $4.72
- Resistance Level
- LPTX $0.37
- CLRB $5.09
- Average True Range (ATR)
- LPTX 0.03
- CLRB 0.38
- MACD
- LPTX -0.00
- CLRB 0.09
- Stochastic Oscillator
- LPTX 28.53
- CLRB 3.42
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.